Skip to content

BREAKING NEWS: FDA Approves First Treatment for Friedreich’s Ataxia. LEARN MORE!

National Ataxia Foundation

2023 AAC

NfL

Developing therapeutically relevant biomarkers for SCA3

Written by Dr Hannah K Shorrock Edited by Dr Vitaliy V Bondar Measuring levels of polyQ ATXN3 proteins in cerebrospinal fluid and plasma distinguishes SCA3 patients from unaffected individuals For disease-modifying medicines or therapies to be approved for use in the clinic, the treatments must demonstrate success at meeting pre-set Read More…

Measuring neurodegeneration in spinocerebellar ataxias

Written by Dr Hannah K Shorrock Edited by Dr. Maria do Carmo Costa Neurofilament light chain predicts cerebellar atrophy across multiple types of spinocerebellar ataxia A team led by Alexandra Durr at the Paris Brain Institute identified that the levels of neurofilament light chain (NfL) protein are higher in SCA1, Read More…

Snapshot: What is Neurofilament light protein (NfL)?

Nerve cells (aka neurons) are unique cells in that they have long, and thin extensions called axons which form connections with and talk to other neurons. This particular shape of neurons determines how quickly they can get their messages to other cells. You can think of the axons in the Read More…

Translate »
National Ataxia Foundation

Join NAF

Become a member for FREE!
It only takes a few moments.

Sign up today to receive:

  • News and research opportunities about your specific type of Ataxia as they become available
  • Early access to free webinars
  • eNewsletter and Generations publications